(Q36756365)

16 August 2017

1 reference

title

Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions (English)

1 reference

16 August 2017

0 references

1

Daniel C Javitt

1 reference

16 August 2017

publication date

1 January 2007

1 reference

International Review of Neurobiology

16 August 2017

published in

1 reference

16 August 2017

volume

78

1 reference

16 August 2017

page(s)

69-108

1 reference

Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Prefrontal dopamine D1 receptors and working memory in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The NMDA antagonist model for schizophrenia: promise and pitfalls.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Modulation of striatal dopamine release in vitro by agonists of the glycineB site of NMDA receptors; interaction with antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Modulation of N-methyl-D-aspartate receptor function by glycine transport

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Neuropsychological deficits in the early course of first episode schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Disruption of prepulse inhibition in mice lacking mGluR1.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Discovery and SAR of org 24598-a selective glycine uptake inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Early-stage visual processing and cortical amplification deficits in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The current status of the dopamine hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The neurochemical circuitry of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Deficit and nondeficit forms of schizophrenia: the concept

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Where do you think you are going? The NMDA-D1 receptor trap

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Association analysis of the genetic variants of the N-methyl D-aspartate receptor subunit 2b (NR2b) and treatment-refractory schizophrenia in the Chinese

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The glutamatergic dysfunction hypothesis for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Dopamine in schizophrenia: a review and reconceptualization

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

COMT genotype and manic symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Variations in the NMDA receptor subunit 2B gene (GRIN2B) and schizophrenia: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Clozapine plus lamotrigine in treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Placebo-controlled trial of glycine added to clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Regulation of Glutamate Carboxypeptidase II Function in Corticolimbic Regions of Rat Brain by Phencyclidine, Haloperidol, and Clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Enhancement of the NMDA receptor function by reduction of glycine transporter-1 expression

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Glutamate Carboxypeptidase II Gene Expression in the Human Frontal and Temporal Lobe in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

D-cycloserine added to clozapine for patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The G72/G30 gene complex and cognitive abnormalities in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The role of glycineB binding site and glycine transporter (GlyT1) in the regulation of [3H]GABA and [3H]glycine release in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Enhancement by an ampakine of memory encoding in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Silent glutamatergic synapses in the mammalian brain

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

A microsatellite repeat in the promoter of the N-methyl-D-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Recent advances in the phencyclidine model of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Inhibition of striatal dopamine release by glycine and glycyldodecylamide

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site Agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Modulation of striatal dopamine release by glycine transport inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Dysregulation of mesoprefrontal dopamine neurons induced by acute and repeated phencyclidine administration in the nonhuman primate: implications for schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Prolonged positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors induces calpain-mediated PSD-95/Dlg/ZO-1 protein degradation and AMPA receptor down-regulation in cultured hippocampal slices

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Baseline neurocognitive deficits in the CATIE schizophrenia trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Is the G72/G30 locus associated with schizophrenia? single nucleotide polymorphisms, haplotypes, and gene expression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Glutamate regulates the spontaneous and evoked release of dopamine in the rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Effects of ketamine in normal and schizophrenic volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Increased dopamine transmission in schizophrenia: relationship to illness phases

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Intracellular modulation of NMDA receptor function by antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Elevated homocysteine levels in young male patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Behavioral effects of chronic phencyclidine in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

No association of G72 and D-amino acid oxidase genes with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Model psychoses and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Different roles of group I and group II metabotropic glutamate receptors on phencyclidine-induced dopamine release in the rat prefrontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Positive association of the AMPA receptor subunit GluR4 gene (GRIA4) haplotype with schizophrenia: linkage disequilibrium mapping using SNPs evenly distributed across the gene region

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Disorders of attention and perception in early schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Clozapine-induced reduction of glutamate transport in the frontal cortex is not mediated by GLAST and EAAC1.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Impact of complex genetic variation in COMT on human brain function.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The NMDA/D1 receptor complex as a new target in drug development.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Molecular mechanism of neuronal plasticity: induction and maintenance of long-term potentiation in the hippocampus

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Bringing order to the glutamate chaos in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Acute Effects of Ketamine on Memory Systems and Psychotic Symptoms in Healthy Volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Distribution of mGluR1alpha and mGluR5 immunolabeling in primate prefrontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Altered prefrontal dopaminergic function in chronic recreational ketamine users

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

NMDA receptor hypofunction model of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Dopamine-mediated regulation of striatal neuronal and network interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Group I metabotropic glutamate receptors in the monkey striatum: subsynaptic association with glutamatergic and dopaminergic afferents.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Biphasic modulation of evoked [3H]D-aspartate release by D-2 dopamine receptors in rat striatal slices

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Differential effects of chronic haloperidol and clozapine administration on glutamatergic transmission in the fronto-parietal cortex in rats: microdialysis and electrophysiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The metabotropic glutamate receptors: structure, activation mechanism and pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Auditory Sensory Dysfunction in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Calcium binding protein markers of GABA deficits in schizophrenia--postmortem studies and animal models

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

A linkage study of the N-methyl-D-aspartate receptor subunit gene loci and schizophrenia in southern African Bantu-speaking families

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Selective cognitive impairments associated with NMDA receptor blockade in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Neuropsychological function in schizophrenia. Selective impairment in memory and learning

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Increased cortical kynurenate content in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Schizophrenia patients demonstrate a distinctive pattern of decision-making impairment on the Iowa Gambling Task

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The involvement of ErbB4 with schizophrenia: association and expression studies

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Neuregulin 1 and susceptibility to schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Auditory sensory ("echoic") memory dysfunction in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Schizophrenia and impaired homocysteine metabolism: a possible association

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Target-specific glutamatergic regulation of dopamine neurons in the ventral tegmental area

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

The AMPAR subunit GluR2: still front and center-stage

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Abnormal excitatory neurotransmitter metabolism in schizophrenic brains

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Gene knockout of glycine transporter 1: characterization of the behavioral phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

D-alanine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Genetic mechanisms of psychosis: in vivo and postmortem genomics

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Prefrontal neurons and the genetics of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Word and tone working memory deficits in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

Adjunctive high-dose glycine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2806%2978003-5

7 January 2021

10.1016/S0074-7742(06)78003-5

Identifiers

DOI

1 reference

16 August 2017

1 reference